Steroid receptors as molecular targets for cancer diagnosis and therapy

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 26, Issue 3, 2009, Pages 207-273

  Mishra, Pramod ^a   Gulbake, Arvind ^a   Jain, Aviral ^a   Khare, Piush ^a   Soni, Vandana ^a   Vyas, S P ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Cancer; Gene therapy; Imaging; Steroid receptors; Steroidal ligands; Targeting

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 [3 (4 HYDROXYBUTYL) 4,4 DIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL] 2 TRIFLUOROMETHYLBENZONITRILE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; CALCITRIOL; CISPLATIN; ESTROGEN RECEPTOR; FINASTERIDE; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; GONADORELIN RECEPTOR; GONADOTROPIN RECEPTOR; GROWTH HORMONE RECEPTOR; LIVER X RECEPTOR; MINERALOCORTICOID RECEPTOR; MITHRAMYCIN; MONOCLONAL ANTIBODY J591; PERILLYL ALCOHOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; PROMEGESTONE; RADICICOL; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RU 56279; RU 59063; STEROID; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; TANESPIMYCIN; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCRINE TUMOR; GENE TARGETING; GENE THERAPY; HUMAN; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; TUMOR;

GENE THERAPY; HUMANS; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, STEROID;

EID: 70349976979     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i3.10     Document Type: Review

References (262)

1. Vyas SP, Sihorkar V. Endogenous carriers and ligands in non-immunogenic site-specifc drug delivery. Adv Drug Del Rev. 2000;43:101-164
2. Escriou V, Carriere M, Scherman D, Wils P. NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv Drug Del Rev. 2003;55:295-306.
3. Hoffmann J, Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer-recent advances, mechanisms of resistance, and new approaches. J Ster Biochem Mol Biol. 2005;93:191-200.
4. Leuschner C, Hansel W. Targeting breast and prostate cancers through their hormone receptors. Biol Reprod. 2005;73:860-865
5. Brix HP, Berger MR, Schneider MR, Tang WC, Eisenbrand G. Androgen-linked alkylating agents: biological activity in methyl-nitrosourea-induced rat mammary carcinoma. J Cancer Res Clin Oncol. 1990;116:538-549
6. Swamy N, James DA, Mohr SC, Hansonc RN, Raya R. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. Bioorg Med Chem. 2002;10:3237-3243
7. Molnar I, Kute T, Williamgham MC, Schwartz GG. 19-Nor-1α, 25-dihydroxy vitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. J Ster Biochem Mol Biol. 2004;89-90:539-543
8. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Synthesis, cellular transport and activity of polyamidoamine dendrimer-methylpredniso-lone conjugates. Bioconjug Chem. 2005;16:330-337
9. Hager GL, Smith CL, Fragoso G, Wolford R, Walker D, Barsony J, Htu H. Intranuclear traffcking and gene targeting by members of the steroid/nuclear receptor superfamily. J Ster Biochem Mole Biol. 1998;65:125-132
10. Freedman LP. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. J Nutri Suppl. 1999;129(2S)581-586
11. Marquis JC, Hillier SM, Dinaut AN, Rodrigues D, Mitra K, Essigmann JM, Croy RG. Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand. Chem Biol. 2005;12:779-787
12. Santos AF, Huang H, Tindall DJ. The androgen receptor: a potential target for therapy of prostate cancer. Steroids. 2004;69:79-85. (Pubitemid 38315080)
13. Granner DK. In: Illustrated biochemistry, the diversity of the endocrine system. New York: McGraw-Hill; 2003. p.434-455
14. Migliaccio A, Castoria G, Domenico MD, Falco AD, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A, Auricchio F. Sex steroid hormones act as growth factors. J Ster Biochem Mol Biol. 2003;83:31-35
15. Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ. 2007;31:26-33.
16. Miller WR, Langdon SP. Steroid hormones and cancer: (III) Observations from human subjects. Eur J Surg Oncol. 1997;23:163-183
17. Berkenstam A, Gustafsson JA. Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr Opin Pharmacol. 2005;5:171-176
18. Tuohimaa P, Blauer M, Pasanen S, Passinen S, Pekki A, Punnonen R, Syvala H, Valkila J, Wallen M, Valiaho J, Zhuang YH, Ylikomi T. Mechanisms of action of sex steroid hormones: basic concepts and clinical correlations. Maturitas. 1996;23(Suppl):S3-12.
19. White R, Parker MG. Molecular mechanisms of steroid hormone action. Endo Rel Cancer. 1998;5:1-14.
20. Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. J Nucl Recep Sig Atlas. 2007;5:1-9.
21. Fuller PJ. The steroid receptor superfamily: mechanisms of diversity. FASEB J. 1991;5:3092-3099
22. Blumberg B, Evans RM. Orphan nuclear receptors-new ligands and new possibilities. Genes Dev. 1998;12:3149-3155
23. Altucci L, Gronemeyer H. Nuclear receptors in cell life and death. Trends Endocrinol Meta. 2001;12:460-468
24. Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C, Andrew R. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthal Vis Sci. 2000;41:1629-1638
25. Stumpf WE. Receptor localization of steroid hormones and drugs: discoveries through the use of thaw-mount and dry-mount autoradiography. Braz J Med Biol Res. 1998;31:197-206.
26. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 2002;16:1429-1431
27. Kidwai N, Gong Y, Sun X, Deshpande CG, Yeldandi AV, Rao MS, Badve S. Expression of androgen receptor and prostate-specifc antigen in male breast carcinoma. Breast Cancer Res. 2004;6:R18-23.
28. Watson CS, Campbell CH, Gametchu B. The dynamic and elusive membrane estrogen receptor-alpha. Steroids. 2002;67:429-437
29. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrin Meta. 2004;15:316-323
30. Ballare C, Vallejo G, Vicent GP, Saragueta P, Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol. 2006;102:2-10.
31. Nicholson RI, McClelland RA, Gee JM. Steroid hormone receptors and their clinical signifcance in cancer. J Clin Pathol. 1995;48:890-895
32. Watson CS, Gametchu B. Membrane estrogen and glucocorticoid receptors implications for hormonal control of immune function and autoimmunity. Int Immunopharmacol. 2001;1:1049-1063
33. Eagon PK, Elm MS, Epley MJ, Shinozuka H, Rao KN. Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterol-ogy. 1996;110:1199-1207 (Pubitemid 26113760)
34. Jacobs E, Watson SA, Hardcastle JD, Robertson JFR. Oestrogen and progesterone receptors in gastrointestinal cancer cell lines. Eur J Cancer. 1996;32:2348-2353
35. Beato M, Chavez S, Truss M. Transcriptional regulation by steroid hormones. Steroids. 1996;61:240-251
36. Orti E, Bodwell JE, Munck A. Phosphorylation of steroid hormone receptors. Endocrine Rev. 1992;13:105-128
37. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81:1269-1304
38. Lee KC, Kraus WL. Nuclear receptors, coactivators and chromatin: new approaches, new insights, Trends Endocrin Meta. 2001;12:191-197
39. Mckenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999;20:321-344
40. Bagchi MK, Tsai MJ, O'Malley BW, Tsai SY. Analysis of the mechanism of steroid hormone receptor-dependent gene activation in cell-free systems. Endocr Rev. 1992;13:525-535
41. Chen HC, Farese RV Jr. Steroid hormones: Interactions with membrane-bound receptors. Curr Biol. 1999;9:R478-81.
42. Cenni B, Picard D. Ligand-independent activation of steroid receptors: new roles for old players. TEM. 1999;10:41-46
43. Philips A, Chalbos D, Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem. 1993;268:14103-14108
44. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specifc estrogen-like effects of antiestrogens. Mole Endocr. 1995;9:443-456
45. Stein B, Yang MX. Repression of the Interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol. 1995;15:4971-4979
46. Pietras RJ, Nemere I, Szego CM. Steroid hormone receptors in target cell membranes. Endocrine. 2001;14:417-427
47. Leader JE, Wang C, Fu M, Pestell RG. Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol. 2006;72:1589-1596
48. Kim SH, Tamrazi A, Carlson KE, Katzenellenbogen JA. A proteomic microar-ray approach for exploring ligand-initiated nuclear hormone receptor pharmacology, receptor selectivity, and heterodimer functionality. Mol Cell Prot. 2005;4:267-277
49. Hermanson O, Glass CK, Rosenfeld MG. Nuclear receptor coregulators: multiple modes of modifcation. TRENDS Endocrin Meta. 2002;13:55-60.
50. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465-74.
51. Fu M, Wang C, Zhang X, Pestell RG. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol. 2004;68:1199-1208.
52. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Devel. 1999;9:140-147
53. Beato M, Klug J. Steroid hormone receptors: an update. Human Reprod Update. 2000;6:225-236
54. Gao X, Loggieand BW, Nawaz Z. The roles of sex steroid receptor coregulators in cancer. Mol Cancer. 2002;1:1-7.
55. Petrak K. Essential properties of drug targeting systems. Drug Del/ Technol. 2005;10:1667-1735
56. Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Res Update. 2008;8:219-233
57. Davidson NE, Visvanathan K, Emens L. New fndings about endocrine therapy for breast cancer. Breast. 2003;12:368-372
58. O'Rourke Cloutier A. Advanced breast cancer: recent developments in hormonal therapy. 2000. Sem Oneol Nursing. 2000;16:206-213
59. Heldermon C, Ellis M. Endocrine therapy for breast cancer. Update Cancer Ther. 2006;1:285-297
60. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Euro Urol.2007;51:306-314
61. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154-179
62. Droz JP, Flechon A, Terret C. Prostate cancer: management of advanced disease. Ann Oncol. 2002;13:89-94.
63. Whitehead SA. Endocrine-disrupting chemicals as modulators of sex steroid synthesis. Best Prac Res Clin Endo Meta. 2006;20:45-51.
64. Zhang P, Terefenko EA, Fensome A, Wrobel J, Winneker R, Zhang Z. Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. Bioorg Med Chem Lett. 2003;13:1313-1316
65. Dong Y, Roberge JY, Wang Z, Wang X, Tamasi J, Dell V, Golla R, Corte JR, Liu Y, Fang T, Anthony MN, Schnur DM, Agler ML, Dickson JK Jr, Lawrence RM, Prack MM, Seethala R, Feyen JH. Characterization of a new class of selective nonsteroidal progesterone receptor agonists. Steroids. 2004;69:201-207
66. Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z. Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators Bioorg Med Chem Lett. 2007;17:439-443 (Pubitemid 46073744)
67. Hosoda S, Tanatani A, Wakabayashi K, Nakano Y, Miyachi H, Nagasawa K, Hashimoto Y. Ligands with dual vitamin D3-agonistic and androgen-antagonistic activities. Bioorg Med Chem Lett. 2005;15:4327-4331
68. Marwah P, Marwah A, Lardy HA, Miyamoto H, Chang C. C19-steroids as androgen receptor modulators: design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists. Bioorg Med Chem. 2006;14:5933-5947
69. Schmidt JM, Mercure J, Tremblay GB, Pagé M, Feher M, Dunn-Dufault R, Peter MG, Redden PR. De novo design, synthesis and evaluation of a non-steroidal diphenylnaphthyl propylene ligand for the estrogen receptor. Bioorg Med Chem. 2003;11:1389-1396 (Pubitemid 36293533)
70. Sarkhel S, Sharon A, Trivedi V, Maulik PR, Singh MM, Venugopalan P, Ray S. Structure-based drug design: synthesis, crystal structure, biological evaluation and docking studies of mono-and bis-benzo[b]oxepines as non-steroidal estrogens. Bioorg Med Chem. 2003;11:5025-5033
71. Tapolcsanyia P, Wolfing J, Falkay G, Marki A, Minoricsb R, Schneidera G. Synthesis and receptor-binding examination of 16-hydroxymethyl-3,17-estradiol stereoisomers. Steroids. 2002;67:671-678 (Pubitemid 34462995)
72. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459-476 (Pubitemid 39331277)
73. Zhu W, Smith A, Young CYF. A nonsteroidal anti-infammatory drug, fufe-namic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 1999;140:5451-5454 (Pubitemid 30687160)
74. Garnett MC. Targeted drug conjugates: principles and progress. Adv Drug Del Rev. 2001;53:171-216.
75. Molema G, Meijer DKF. Targeting of drugs to various blood cells using (neo) glycoprotein, antibodies and other protein carrier. Adv Drug Del Rev. 1994;14:25-50
76. Vyas SP, Singh A, Sihorkar V. Ligand receptor mediated drug delivery emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carr Syst. 2001;18:1-76.
77. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv Drug Del Rev. 1998;29:273-289
78. Mitra A, Colemanc T, Borgman M, Nan A, Ghandehari H, Line BR. Polymeric conjugates of mono-and bi-cyclic αV β3 binding peptides for tumor targeting. J Cont Rel. 2006;114:175-183
79. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Techno Cancer Res Treat. 2005;4:1533-1546
80. Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. 2005;13:5043-5054
81. Allen TM. Ligand targeted therapeutics. Nature. 2002;2:750-764.
82. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specifc membrane antigen. Cancer Res. 1994;54:1807-1811
83. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specifc membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334
84. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specifc membrane antigen. J Urol. 2003;170:1717-1721 (Pubitemid 37254913)
85. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specifc membrane antigen. J Urol. 2003;170(6 Pt 2):S84-8.
86. Strobl JS, Wonderlin WF, Flynn DC. Mitogenic signal transduction in human breast cancer cells. Gen Pharmacol. 1995;26:1643-1649
87. Murphy LC, Watson P. Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother. 2002;56:65-77.
88. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616
89. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endo Rel Cancer. 2003;10:209-216
90. Swinnen JV, Heemers H, Van de Sande T, De Schrijver E, Brusselmans K, Heyns W, Verhoeven G. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol. 2004;92(4):273-279
91. Rae MT, Hillier SG. Steroid signalling in the ovarian surface epithelium. Trends Endocr Meta. 2005;16:327-333
92. Lemieux P, Fuqua S. The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol. 1996;56:87-91.
93. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Mol Biol. 1998;65:163-168
94. Jones BB, Petkovich M. Targeting transcription through nuclear receptors. Cancer Res. 1996;2:156-168
95. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience. 2007;145:795-811.
96. Fukuta M, Okada H, Iinuma S, Yanai S, Toguchi H. Insulin fragments as a carrier for peptide delivery across the blood-brain barrier. Pharm Res. 1994;11:1681-1688
97. Das T, Banerjee S, Samuel G, Bapat K, Subramanian S, Pillai MRA, Ven-katesh M. A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors. Bioorg Med Chem Lett. 2006;16:5788-5792
98. Schally AV, Comaru-Schally AM. Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Adv Drug Del Rev. 1997;28:157-169
99. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrin Meta. 2004;15:300-310
100. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Ster Biochem Mole Biol. 2006;102:156-162
101. Bai C. ASSAY and drug development technologies. steroid hormone receptors and drug discovery: therapeutic opportunities and assay designs. 2003;1:843-852
102. Katzenellenbogen JA, Muthyala R. Interactions of exogenous endocrine active substances with nuclear receptors. Pure Appl Chem. 2003;75:1797-1817
103. Thorpe PE, Derbyshire EJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang YC, Rao-Betté M. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 1993;53:3000-3007
104. Tang W, Schneider MR, Eisenbrand G. Novel steroid-linked conjugates of 17 beta-[N-[N'-(2-chloroethyl)-N'-nitroso]carbamoyl]amino acids and their antineoplastic activity against Noble Nb prostate carcinoma model in rats. Anticancer Drug Des. 1998;13:815-824
105. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Rel Cancer. 2006;13:653-666
106. Ellis MJ. Selective aromatase inhibitors: current indication and future perspectives. Diseases Breast Update. 1998;2:1-11.
107. Osborne CK. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Rel Cancer. 1999;6:271-276
108. Simpson ER, Dowsett M. Aromatase and its inhibitors: signifcance for breast cancer therapy. Recent Prog Horm Res. 2002;57:317-338 (Pubitemid 35051827)
109. Pasqualini JR, Gelly C, Nguyen BL, Vella C. Importance of estrogen sulfates in breast cancer. J Steroid Biochem. 1989;34:6155-6163
110. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev. 2005;26:171-202.
111. Schreiner EP, Billich A. Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett. 2004;14:4999-5002.
112. Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE, Miller WL. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A. 1987;84:407-411
113. Coster RD, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol. 1996;56:133-143
114. Wachall BG, Hector M, Zhuang Y, Hartmann RW. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Bioorg Med Chem Lett. 1999;7:1913-1924
115. Kenny B, Ballard S, Blagg J, Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem. 1997;40:1293-1315
116. Rhodes L, Harper J, Uno H, Gaito G, Audette-Arruda J, Kurata S, Berman C, Primka R, Pikounis B. The effects of fnasteride (proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail Macaques (1 Macezca arctoides). J Clin Endocrinol Metab. 1994;79:991-996
117. Jones CD, Audia JE, Lawhorn DE, McQuaid LA, Neubauer BL, Pike AJ, Pen-nington PA, Stamm NB, Toomey RE, Hirsch KS. Nonsteroidal inhibitors of human type i steroid 5-α-reductase. J Med Chem. 1993;36:421-423
118. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5oi-reductases. Proc Natl Acad Sci U S A. 1990;87:3640-3644
119. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestoster-one in human prostatic hyperplasia is not supranormal. J Clin Invest. 1983;72:1772-1777
120. Tian W, Zhu Z, Liao Q, Wu Y. A practical synthesis of 3-substituted A3"5(6)-steroids as new potential 5α-reductase inhibitor. Bioorg Med Chem Lett. 1998;8:1949-52.
121. Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs. 1999;57:557-581
122. Smith ECR, McQuaid LA, Goode RL, McNulty AM, Neubauer BL, Rocco VP, Audia JE. Synthesis and 5α-reductase inhibitory activity of 8-substituted Benzo[f]]quinolinones derived from palladium mediated coupling reactions. Bioorg Med Chem Lett. 1998;8:395-398
123. Baston E, Palusczak A, Hartmann RW. 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5a reductases types 1 and 2 Eur J Med Chem. 2000;35: 931-940
124. Picard F, Schulz T, Hartmann RW. 5-Phenyl substituted 1-methyl-2-pyridones and 4 0-substituted biphenyl-4-carboxylic acids-synthesis and evaluation as inhibitors of steroid-5 αreductase type 1 and 2. Bioorg Med Chem. 2002;10:437-448
125. Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5alpha-reductase, 20alphahydroxysteroid oxidoreductase and 3 alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer. 2003;3:1-15.
126. Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol. 2005;93:201-208
127. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498
128. Geistlinger TR, McReynolds AC, Guy RK. Ligand-selective inhibition of the interaction of steroid receptor coactivators, and estrogen receptor isoforms. Chem Biol. 2004;11:273-281
129. Wang LG, Ferrari AC. Mithramycin targets Sp1 and the androgen receptor transcription level-potential therapeutic role in advanced prostate cancer. Translational Oncogen. 2006;2:19-31.
130. Lee SH, Hannink M. Molecular mechanisms that regulate transcription factor localization suggest new targets for drug development. Adv Drug Del Rev. 2003;55:717-731
131. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18:306-360
132. Scheibel T, Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochemical Pharmacol. 1998; 56:675-682
133. Darimont BD. The Hsp90 chaperone complex-A potential target for cancer therapy. World J Gastroent. 1999;5:195-198
134. Rosenhagen MC, Soti C, Schmidt U, Wochnik GM, Hartl FU, Holsboer F, Young JC, Rein T. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol. 2003;17:1991-2001.
135. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res. 2001;7:2076-2084
136. Knight ZA, Shokat KM. Features of selected kinase 263, inhibitors. J Chem Biol. 2005;12:621-637
137. Cavailles V, Dauvois S, Danielian PS, Parker MG. Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci U S A. 1994;91:10009-10013
138. Chung LWK, Hsieh Chia-Ling, Law A, Sung Shian-Ying, Gardner TA, Egawa M, Matsubara S, Zhau HE. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology. 2003;62 (Suppl 5a):44-54.
139. Berube G. Natural and synthetic biologically active dimeric molecules: anti-cancer agents, anti-HIV agents, steroid derivatives and opioid antagonists. Curr Med Chem. 2006;13:131-154
140. Chung BH, Lee Hye-young, Leea JS, Young CYF. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2006;236:222-228
141. Fleming S. The molecular biology of cancer: the basics. Surgery. 2003;21:1-6.
142. Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Adv Drug Del Rev. 1999;37:189-211.
143. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids. 1993;58:245-259
144. Katzenellenbogen JA, Coleman RE, Howkins RA, Krohn KA, Larson SN, Mendelson J, Osborne CK, Piwnika-Worms D, Reba RC, Siegel BA, Welch MJ, Schtern F. Tumor receptor imaging: proceedings of the national cancer institute workshop: review of current work, and prospective for further investigations. Clin Cancer Res. 1995;1: 921-932
145. Bergqvist A, Carlstrom K, Ljungberg O. Histochemical localization of estrogen and progesterone receptors: evaluation of a method. J Histochem Cytochem. 1984;32:493-500.
146. Castanas E. Steroid conjugates preparation thereof and the use thereof. United States patent US 7358379 B2. 2006.
147. Katzenellenbogen JA. Steroids labeled with 18F for imaging tumors by positron emission tomography. J Fluorine Chem. 2001;109:49-54.
148. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ. Positron tomo-graphic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774
149. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic fare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56
150. Bonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, Choe YS, Katzenellenbogen JA, Welch MJ. Preclinical evaluation of fuorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015
151. Buckman BO, Bonasera TA, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin 16α.l7α-dioxolanes: development of high affnity ligands for the progesterone receptor with high, in vivo target site selectivity. J Med Chem. 1995;38:328-337
152. Choe YS, Bonasera TA, Chi DY, Welch MJ, Katzenellenbogen JA. 6α-18F Fluoroprogesterone: synthesis via halofuorination-oxidation, receptor binding and tissue distribution. Nucl Med Biol. 1995;22:635-642
153. Garg PK, Labareec DC, Hoyted RM, Hochbergc RB. [7a-18F] fuoro-17a-methyl-5a-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol. 2001;28:85-90.
154. Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16α-[18F]-fuoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26:905-913
155. Van Dort ME, Jung Y-W. Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands. Bioorg Med Chem Lett. 2004;14:5285-5288
156. Van Den Bos JC, Rijks LJM, Van Doremalen PAPM, Bruin KD, Janssen AGM, Royen EAV. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 1: synthesis and in vitro pharmacological characterization. Nucl Med Biol. 1998;25:781-789
157. Banerjee S, Das T, Chakraborty S, Samuel G, Korde A,Venkatesha M, Pillai MRA. An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent. Bioorg Med Chem. 2005;13: 4315-4322
158. Osella D, Nervi C, Milone L, Galeotti F, Vessieres A, Jaouen G. The Co3(CO)9C moiety acts as an electroreducible marker for estradiol detection enhancement in the HPLC-ED technique. J Organomet Chem. 2000;593-594:232-239
159. Wuest F, Skadda MB, Leibnitz P, Spies H, Katzenellenbogen JA, Johannsen B. Synthesis of novel progestin±rhenium conjugates as potential ligands for the progesterone receptor. Bioorg Med Chem. 1999;7:1827-1835
160. Spradau TW, Katzenellenbogen JA. Ligands for the estrogen receptor, containing Cyclopentadienyltricarbonylrhenium units. Bioorg Med Chem Lett. 1998;8:3235-3240
161. Top S, Hafa HE, Vessieres A, Quivy J, Vaissermann J, Hughes DW, McGlinchey MJ, Mornon J-P, Thoreau E, Jaouen G. Rhenium carbonyl complexes of beta-estradiol derivatives with high affnity for the estradiol receptor: an approach to selective organometallic radiopharmaceuticals. J Am Chem Soc. 1995;117:8372-8380
162. Tuozzi A, Sterzo CL, Sperandio A, Bocelli G. Use of the Stille coupling to label steroids with the thynylcyclopentadienylmanganesetricarbonyl moiety. Tetrahedron. 1999;55:461-474
163. Lashley MR, Niedzinski EJ, Rogers JM, Denison MS, Nantz MH. Synthesis and estrogen receptor affnity of a 4-hydroxytamoxifen-labeled ligand for diagnostic imaging. Bioorg Med Chem. 2002;10:4075-4082
164. Quivy J, Leclercq G, Deblaton M, Henrot P, Velings N, Norberg B, Evrard G, Zeicher M. Synthesis, structure and biological properties of Z-17alpha-(2-iodovinyl)-11beta-chloromethyl estradiol-17beta (Z-CMIV), a high affnity ligand for the characterization of estrogen receptor-positive tumors. J Steroid Biochem Mol Biol. 1996;59:103-117
165. Sinhababu AK, Thakker DR. Prodrugs of anticancer agents. Adv Drug Del Rev. 1996;19:241-273
166. Bursi R, Groen MB. Application of (quantitative) structure-activity relationships to progestagens: from serendipity to structure-based design. Eur J Med Chem. 2000;35:787-796
167. Dea S, Macara IG, Lannigan DA. Novel biosensors for the detection of estrogen receptor ligands. J Steroid Biochem Mole Biol. 2005;96: 235-244
168. Bescth B. The pharmacokinetic model and distribution pattern of new sexual-steroid-hormone-linked anticancer agents. J Cancer Res Clin Oncol. 1990;116:467-469
169. Eisenbrand G, Berger MR, Brix HP, Fischer JE, Mühlbauer K, Nowrousian MR, Przybilski M, Schneider MR, Stahl W, Tang W. Nitrosoureas. Modes of action and perspectives in the use of hormone receptor affnity carrier molecules. Acta Oncol. 1989;28:203-211
170. Rai S, Paliwal R, Vaidya B, Gupta PN, Mahor S, Khatri K, Goyal AK, Rawat A, Vyas SP. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery. Current Med Chem. 2007; 14(19):2095-2109
171. Leblanc GA, Gooding MP, Sternberg RM. Testosterone-fatty acid esterifcation: a unique target for the endocrine toxicity of tributyltin to gastropods. Integr Comp Biol. 2005;45:81-87
172. Fujiwara T, Hirshima N, Hasegava S, Nakanishi M, Ohwada T. Space flling effect in membrane disruption by cationic amphiphiles. Bioorg Med Chem. 2001;9:1013-1024
173. Jansson S E, Gripenberg J, Karonen SL, Wasenius VM, Pantzar P, Kontula K, Kärkkäinen J, Adlercreutz H. Cytochemical demonstration of estrogen binding sites in breast cancer by estradiol covalently linked to horseradish peroxidase. Eur J Cancer Clin Oncol. 1985;21:625-630
174. Devanesan P, Todorovic R, Zhao J, Gross ML, Rogan EG, Cavalieri EL. Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogen-initiated cancer. Carcinogenesis. 2001;22:489-497 (Pubitemid 32203830)
175. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-SRC heteroprotein complex formation by benzoqui-none ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994;91:8324-8328
176. Galigniana MD, Scruggs JL, Herrington J, Welsh MJ, Carter-Su C, Housley PR, William B. Heat Shock Protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Pratt Molecula Endocrin. 1998;12:1903-1913
177. Kuduk SD, Zheng FF, Sepp-Lorenzino L, Rosen N, Danishefsky SJ. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999;9:1233-1238
178. Kuduk SD, Harris CR, Zheng FF, Sepp-Lorenzino L, Ouerfelli Q, Rosen N, Danishefsky SJ. Synthesis and evaluation of geldanamycin±testosterone hybrids. Bioorg Med Chem Lett. 2000;10:1303-1306
179. Sharma U, Marquis JC, Dinaut AN, Hillier SM, Fedeles B, Rye PT, Essigmann JM, Croy RG. Design, synthesis, and evaluation of estradiol-linked genotoxi-cants as anti-cancer agents. Bioorg Med Chem Lett. 2004;14:3829-3833
180. Rink SM, Yarema KJ, Solomon MS, Paige LA, Tadayoni-Rebek M, Essigmann JM, Croy RG. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proc Natl Acad Sci U S A. 1996;93:15063-15068
181. Rubin EH, Hait WN. In: Bast, R.C. ed. Anthracyclines and DNA intercalators/ epipodophyllotoxins/camptothecins/DNA topoisomerases. New York: Decker. 2000; p. 670-679
182. Kasiotisa KM, Magiatisb P, Pratsinisb H, Skaltsounisb AL, Abadjic V, Charal-ambous A, Moutsatsoub P, Haroutouniana SA. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids. 2001;66:785-791
183. Cogan PS, Koch TH. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specifc delivery of a doxorubicin-formaldehyde conjugate. J Med Chem. 2003;46:5258-5270
184. Rajkowski KM, Cittanova N, Desfosses B, Jayle MF. The conjugation of testosterone with horseradish peroxidase and a sensitive enzyme assay for the conjugate. Steroids. 1977;29:701-713
185. Amory JK, Scriba GK, Amory DW, Bremner WJ. Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. J Androl. 2003;24:716-720
186. Sharmana WM, Van Liera JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Del Rev. 2004;56:53-76
187. Kinsella TJ, Colussi VC, Oleinick NL, Sibata CH. Photodynamic therapy in oncology. Expert Opin Pharmacother. 2001;2:917-927
188. James DA, Swamy N, Paz N, Hanson RN, Ray R. Synthesis and estrogen receptor binding affnity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer. Bioorg Med Chem Lett. 1999;9: 2379-2384
189. Ishiki N, Onishi H, Machida Y. Antitumor activities of conjugates of mitomycin c with estradiol benzoate and estradiol via glutaric acid in suspension dosage form. Biol Pharm Bull. 2002;25:1373-1377
190. Ishiki N, Onishi H, Machida Y. Biological properties of conjugates of mitomy-cin C with estradiol benzoate and estradiol: their stability characteristics in biological media and their binding abilities to estrogen receptor. Biol Pharm Bull. 1997;20:1096-1102
191. Ishiki N, Onishi H, Machida Y. In vivo properties of the conjugates of mitomy-cin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180. Biol Pharm Bull. 1998;21:1180-1186
192. Ishiki N, Onishi H, Machida Y. Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates. Int J Pharmac. 2004;279:81-93.
193. Macky TA, Soliman MM, Oelkers C, Heredia ML, Kunzel E, Rohrer B, Crosson CE, Rohr J. A novel mitomycin C-triamcinolone conjugate for the prevention of proliferative vitreoretinopathy: in-vitro effcacy and rat retinal toxicity. EVRS Educat Electr J. 2004;1:18-27.
194. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797-1805
195. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667
196. Liu C, Strobl JS, Bane S, Schilling JK, McCracken M, Chatterjee SK, Rahim-Bata R, Kingston DGI. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. J Nat Prod. 2004;67:152-159
197. Wang Z, Yang D, Mohanakrishnan AK, Fanwick PE, Nampoothiri P, Hamel E, Cush-man M. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. J Med Chem. 2000;43:2419-2429
198. Naik H, Lehr JE, Pienta KJ. Inhibition of prostate cancer growth by 9-amin-ocamptothecin and estramustine. Urology. 1996;48:508-511 (Pubitemid 26317501)
199. Von Schoultz E, Lundgren E, Henriksson R. Effects of estramustine and its constituents on human malignant glioma cells. Anticancer Res. 1990;10:693-696
200. Troisi L, Vasapollo G, El Ali B, Mele G, Florio S, Capriati V. Palladium (II) catalysed regioselective lactonization of steroids: chemo-selective construction of novel estrone derivative. Tetrahedron Lett. 1999;40:1771-1774
201. Leese MP, Leblond B, Newmanb SP, Purohit A, Reed MJ, Potter BVL. Anti-cancer activities of novel D-ring modifed 2-substituted estrogen-3-O-sulfamates. J Ster Biochem Mol Biol. 2005;94:239-251
202. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel. 2000;65:271-284
203. Rai S, Paliwal R, Vaidya B, Khatri K, Gupta PN, Goyal AK, Vyas SP. Targeted delivery of doxorubicin via estrone appended liposomes. J Drug Target. 2008;16:455-463
204. Masters JR, Koberle B. Curing metastatic cancer lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003;3:517-525
205. Roth T, Tang W, Eisenbrand G. Synthesis of novel androgen-linked phos-phoramide mustard prodrugs and growth inhibitory activity in human breast cancer cells. Anticancer Drug Des. 1995;10:655-656
206. Janina BK, Zbigniew K. Cancer specifc radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer. United States patent US 7,220,730. 2007.
207. Kuo PL, Hsu YL, Kuo YC, Chang CH, Lin CC. The anti-proliferative inhibition of ellipticine in human breast MDA-MB-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs. 2005;16:789-795
208. Devraj R, Barrett JF, Fernandez JA, Katzenellenbogen JA, Cushman M. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. J Med Chem. 1996;39:3367-3374
209. Akaza H, Imada S, Tsukamoto S, Koiso K. Inhibitory effects of bestrabucil, a conjugate of chlorambucil and estradiol, on the production of androgen-induced growth factor(s) by Shionogi carcinoma 115 cells. Int J Urol. 1994;1(1):67-73.
210. Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: implications for hormonal carcinogenesis. Free Rad Biol Med. 1998;24:341-348
211. Dullin A, Dufrasne F, Gelbcke M, Gust R. Enantiomerically pure [1, 2-diamino-1-(4-fuorophenyl)butane.platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines. Arch Pharm (Weinheim). 2004;337:654-667
212. Dullin A, Dufrasne F, Gelbcke M, Gust R. Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-ethylbutane] platinum(II) complexes. Chem Med Chem. 2006;1:644-653
213. Gabano E, Cassino C, Bonetti S, Prandi C, Colangelo D, Ghiglia AL, Osella D. Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes. Org Biomol Chem. 2005;3:3531-3539
214. Perron V, Rabouin D, Asselin E, Parent S, C-Gaudreault R, Berube G. Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and-independent breast tumor cells. Bioorg Chem. 2005;33:1-15.
215. Cassino C, Gabano E, Ravera M, Cravotto G, Palmisano G, Vessieres A, Jaouen G, Mundwiler S, Alberto R, Osella D. Platinum(II) and technetium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery. Inorg Chimi Acta. 2004;357:2157-2166
216. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res. 2000;6:326-334
217. Singh V, Sairam MR, Bhargavi GN, Akhras RG. Hormonotoxins: preparation and characterization of ovine luteinizing hormone-gelonin conjugate. J Biol Chem. 1989;264:3089-3095
218. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specifc antibody-toxin fusion protein on human prostate cancer cells. Prostate. 2001;47:21-28
219. Li, Shyh-Dar L, Ae-June W, Chung-Kung L. Drug delivery system targeting to estrogen receptor over-expressed cells. United States patent US 20040166167. 2004.
220. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellen-bogen JA Katzenellenbogen BS. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocr. 2006; 20:491-502.
221. McKusick VA. In: Mendelian inheritance in man, 8th ed, Baltimore: Johns Hopkins University Press; 1988. p. 172-173
222. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev. 2007;33:230-283
223. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 2000;16:174-181
224. Basik M, Caplen NJ, Kallioniemi OP, Mousses S. Amplifed genes as therapeutic targets in cancer. TARGETS. 2003;2:147-153
225. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Del Rev. 2001;53:135-154
226. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. New Eng J Med. 2001;344:783-792
227. Hung M-C, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, Yu D. HER-2/neu-targeting gene therapy-a review. Gene. 1995;159:65-71.
228. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A. 1990;87:4499-4503
229. Matin A, Hung MC. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Diff. 1993;4:1051-1056
230. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets. 2003;3:163-175
231. Napoli S, Negri1 U, Arcamone F, Capobianco ML, Carbone GM, Catapano CV. Growth inhibition and apoptosis induced by aunomycin-conju-gated triplex-forming oligonucleotides targeting the C-MYC gene in prostate cancer cells. Nucleic Acids Res. 2006;34:2734-2744
232. Stoff-Khalili MA, Stoff A, Rivera1 AA, Banerjee NL, Everts M, Young S, Siegal GP, Richter DF, Wang M, Dall P, Mathis JM, Zhu ZB, Curiel DT. Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system. Breast Cancer Res. 2005;7:R1141-52.
233. Huang J, Li X, Yi1 P, Hilf R, Bambara RA, Muyan M. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol Cell Endocrin; 2004;218:65-78.
234. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab. 2006;17:236-242 (Pubitemid 44080616)
235. Barzon L, Bonaguro R, Palu G, Boscaro M. New perspectives for gene therapy in endocrinology. Eur J Endocrinol. 2000;143:447-466
236. Harrington KJ, Linardakis E, Vile RG. Transcriptional control: an essential component of cancer gene therapy strategies? Adv Drug Del Rev. 2000;44:167-184
237. Rebuffat A, Bernasconi A, Ceppin M, Wehrli H, Verca SB, Ibrahim M, Frey BM, Frey1 FJ, Rusconi S. Selective enhancement of gene transfer by steroid-mediated gene delivery. Nat Biotechnol. 2001;19:1155-1161
238. Rebuffat AG, Nawrocki AR, Nielsen PE, Bernasconi AG, Bernal-Mendez E, Frey BM, Frey FJ. Gene delivery by a steroid-peptide nucleic acid conjugate. FASEB J. 2002;1426-1514
239. Hattori Y, Maitani Y. Enhanced in vitro DNA transfection effciency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Cont Rel. 2004;97:173-183
240. Seraj MJ, Umemoto A, Tanaka M, Kajikawa A, Hamada K, Monden Y. DNA adduct formation by hormonal steroids in vitro. Mutation Res. 1996;370:49-59.
241. Bernasconi A, Rebuffat A, Bigler P, Freya FJ, Freya BM. Synthesis of a dexamethasone-21-maleimido-linked derivative asa potential molecule for specifc gene delivery. Tetrahedron Lett. 2001;42:6511-6513
242. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tie-fenthaler M, Bartsch G, Klocker H. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 2000;7:997-1007.
243. Bhatia D, Yue-Ming L, Ganesh KN. Steroid-DNA conjugates: improved triplex formation with 5-amido-(7-deoxycholic acid)-du incorporated oligonucleotides. Bioorg Med Chem Lett. 1999;9:1789-1794
244. Lamb CA, Helguero LA, Giulianelli S, Soldati R, Vanzulli SI, Molinolo A, Lanari C. Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Breast Cancer Res. 2005;7:1111-1121
245. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol. 1997;23:953-959
246. Eder IE, Hoffman J, Roatsch H, Schafer G, Zopf D, Bartsch G, Klocker H. Inhibition of LNCaP prostate tumor growth in vivo an antisense oligonucle-otide directed against the human androgen receptor. Cancer Gene Therapy. 2002;l9:117-125
247. Haaga P, Frauscher F, Gradl J, Seitz A, Schafer G, Lindner JR, Klibanov AL, Bartsch G, Klocker H, Eder IE. Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol. 2006;102:103-113
248. Lu PY, Xie FY, Woodle MC. SiRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther. 2003;5:225-234
249. Bisanz K, Yu J, Edlund M, Spohn B, Hung M-C, Chung LWK, Hsieh C-L. Interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Therapy. 2005;12:634-643
250. Lorenz C, Hadwiger P, John M, Vornlochera H-P, Unverzagtb C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett. 2004;14:4975-4977
251. Koster F, Felberbaum R, Finas D, Wünsch K, Schulz C, Diedrich K, Hauser C. Progesterone and estradiol enhance lipid mediated transfection of Sk-Br-3 mammarian cancer cells. Int J Mole Med. 2002;9:617-620
252. Koster F, Schrodera A, Finas D, Hauser C, Diedrich K, Felberbaum R. Cell-specifc enhancement of liposomal transfection by steroids in steroid receptor expressing cells. Int J Mol Med. 2006;18:1201-1205
253. Baumann CT, Lim CS, Hager GL. Intracellular localization and traffcking of steroid receptors. Cell Biochem Biophys. 1999;31:119-127
254. Koster F, Finas D, Schulz C, Hauser C, Diedrich K, Felberbaum R. Additive effect of steroids and cholesterol on the liposomal transfection of the breast cancer cell line T-47D. Int J Mol Med.2004;14:769-772
255. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD,Pavlakis GN. Improved DNA: liposome complexes forincreased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652
256. Maillard S, Gauduchonb J, Marsaud V, Gouilleux F, Connault E, Opolon P, Fattal E, Sola B, Renoir J-M. Improved antitumoral properties of pure anti-estrogen RU 58668-loaded liposomes in multiple myeloma. J Steroid Biochem Mol Biol. 2006;100:67-78.
257. Reddy BS, Banerjee R. 17-β-estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chem Int. Ed. 2005;44:6723-6727
258. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharma Des. 2003;9:455-466
259. Sowery RD, So AI, Gleave ME. Novel therapies in advanced prostate cancer. Euro Asso Uro Euro Board Uro. Update series. 2006;4:161-170
260. Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, Piccart MJ. The pipeline of new anticancer agents for breast cancer treatment in 2003. Crit Rev Onco/ Hemato. 2003;48:45-63.
261. Van Der Poel HG. Smart drugs in prostate cancer. Euro Urol. 2004;45:1-17
262. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. EJSO. 2006;32:875-886